M&A / Deals Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling pharminent May 21, 2026
M&A / Deals Regeneron signs $2.32bn deal with Parabilis for Helicon conjugates pharminent May 19, 2026
M&A / Deals Regeneron, Parabilis set out to create new drug class in deal worth up to $2.3B pharminent May 18, 2026
M&A / Deals Degron adds $40M to series A, supporting immunology plans for molecular glue platform pharminent May 14, 2026
M&A / Deals Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion pharminent May 12, 2026
M&A / Deals UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies pharminent May 7, 2026
M&A / Deals Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline pharminent May 6, 2026
M&A / Deals CellCentric secures $220M in Europe’s biggest private biotech fundraise of 2026 pharminent May 6, 2026
M&A / Deals CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine pharminent May 6, 2026
M&A / Deals Amneal Agrees to Acquire Kashiv BioSciences for Total Payment up to $1.1 Billion pharminent May 4, 2026
M&A / Deals UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases pharminent May 4, 2026
